23 October 2017
09 October 2017
IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…) »
28 September 2017
IntegraGen has announced its results for the first half of 2017.
07 September 2017
IntegraGen today announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the E.U., the first positive theranostic test for patients with metastatic colorectal cancer.
Click here for press release
04 August 2017
IntegraGen will be participating the 17th Large and Midcap Event – Paris being held on 6 and 7 October 2017 at the Palais Brongniart.
02 June 2017
The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The convention brings together a wide spectrum of life science and application areas including genomics, drug discovery, (…) »
28 April 2017
IntegraGen informs its shareholders and the financial community that its 2016 Annual Financial Report has been filed with the AMF.
21 April 2017
IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%)
IntegraGen has announced its financial results for the year ending December 31, 2016. The financial statements were validated by the Company’s Board of Directors on April 20, 2017.
08 March 2017
Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p tumor expression test
IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…) »
03 February 2017
IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by (…) »